• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Scientific Publications by FDA Staff

  • Print
  • Share
  • E-mail
-

Search Publications



Fields



Centers











Starting Date


Ending Date


Order by

Entry Details

Clin Pharmacol Ther 2019 Dec 23 [Epub ahead of print]

Comparative outcomes of treatment initiation with brand versus generic warfarin in older patients.

Desai RJ, Gopalakrishnan C, Dejene S, Sarpatwari AS, Levin R, Dutcher SK, Wang Z, Wittayanukorn S, Franklin JM, Gagne JJ

Abstract

The anticoagulant response to warfarin, a narrow therapeutic index drug, increases with age, which may make older patients susceptible to adverse outcomes resulting from small differences in bioavailability between generic and brand products. Using US Medicare claims linked to electronic medical records from two large hospitals in Boston, we designed a cohort study of >/=65-year-old patients. Patients were followed for a composite effectiveness outcome of ischemic stroke or venous thromboembolism, a composite safety outcome including major hemorrhage, and a 1-year all-cause mortality outcome. After propensity score fine-stratification and weighting to account for >90 confounders, hazard ratios comparing brand versus generic warfarin initiators (95% confidence intervals) for the effectiveness, safety, and all-cause mortality outcomes, were 0.97 (0.65-1.46), 0.94 (0.65-1.35), and 0.84 (0.62-1.13), respectively. Results from subgroup analyses of patients with atrial fibrillation, CHADS-VASc score >/= 3, and HAS-BLED score >/= 3 were consistent with the primary analysis.


Category: Journal Article
PubMed ID: #31872419 DOI: 10.1002/cpt.1743
Includes FDA Authors from Scientific Area(s): Drugs
Entry Created: 2019-12-29 Entry Last Modified: 2020-02-02
Feedback
-
-